Affomix Collaborates With City of Hope
Under the collaboration, Affomix is expected to use its automated antibody selection technology to provide City of Hope with recombinant antibodies that are designed to be readily tagged
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.